<DOC>
	<DOCNO>NCT00324116</DOCNO>
	<brief_summary>To evaluate efficacy , base best-corrected visual acuity ( use ETDRS chart ) , 0.3 mg/eye pegaptanib sodium intravitreous injection give every 6 week 54 week patient exudative age-related macular degeneration evidence recent onset , subfoveal and/or juxtafoveal choroidal neovascularization .</brief_summary>
	<brief_title>Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Clinical angiographic evidence juxtafoveal subfoveal choroidal neovascularization secondary AMD total lesion size le 2 MPS disc area Bestcorrected visual acuity study eye great 54 letter ( ETDRS ) Women must use 2 form effective contraception Adequate hematological , renal liver function Any atrophy fibrosis ; retinal hemorrhage measure 1 disc area Any extrafoveal choroidal neovascularization Any intraocular surgery thermal laser study eye within 3 month enrollment Previous concomitant therapy AMD include PDT verteporfin ( Visudyne ) subfoveal/nonfoveal thermal laser therapy , transpupillary thermotherapy , external beam radiation , submacular surgery . Presence cause choroidal neovascularization , include pathological myopia , ocular histoplasmosis syndrome , angioid streak , choroidal rupture multifocal choroiditis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>